AAV-mediated gene transfer for hemophilia

Area of Science:

• Gene Therapy
• Molecular Medicine
• Hematology

Background:

• Hemophilia B is a genetic bleeding disorder caused by deficiency in factor IX.
• Previous gene transfer attempts for hemophilia faced challenges with long-term expression and therapeutic levels.
• Adeno-associated viral vectors (AAV) have advanced for gene delivery applications.

Purpose of the Study:

• To establish an experimental basis for AAV-mediated gene transfer for hemophilia B treatment.
• To assess the efficacy and safety of muscle-directed AAV gene transfer in preclinical models and initiate a clinical trial.

Main Methods:

• Engineered AAV vectors expressing human and canine factor IX.
• Intramuscular injection of AAV vectors into immunodeficient mice and dogs with hemophilia B.
• Dose-escalation clinical trial in human subjects with hemophilia B.

Main Results:

• Sustained expression of factor IX was observed in mice following intramuscular AAV vector delivery.
• Canine factor IX levels increased dose-dependently in dogs with hemophilia B, with prolonged expression (>3 years) at the highest dose.
• Early clinical trial results showed no toxicity, with evidence of gene transfer and expression in muscle biopsies.

Conclusions:

• AAV-mediated, muscle-directed gene transfer is a viable approach for treating hemophilia B.
• Preclinical data support the potential for therapeutic levels of factor IX expression.
• The ongoing clinical trial aims to determine a safe and effective dose for hemophilia B patients.